Phase II study of bevacizumab (BEV), temozolomide (TMZ) and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) Meeting Abstract
| Authors: | Beal, K.; Omuro, A.; Karimi, S.; Correa, D.; Chan, T. A.; Deangelis, L. M.; Yamada, Y.; Abrey, L. E.; Gutin, P. H. |
| Abstract Title: | Phase II study of bevacizumab (BEV), temozolomide (TMZ) and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) |
| Meeting Title: | 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO) |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 81 |
| Issue: | 2 Suppl. |
| Meeting Dates: | 2011 Oct 2-6 |
| Meeting Location: | Miami Beach, FL |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-10-01 |
| Start Page: | S129 |
| ACCESSION: | WOS:000296411700260 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.ijrobp.2011.06.266 |
| Notes: | --- - Meeting Abstract: 260 - S - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
